Related Experiment Video
Updated: Jun 25, 2026
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Association between migraine and a functional polymorphism at the dopamine beta-hydroxylase locus
F Fernandez1, N Colson, S Quinlan
1Genomics Research Centre, Griffith Institute for Health and Medical Research, Griffith University, Gold Coast, 9726 Queensland, Australia.
Neurogenetics
|February 17, 2009
Summary
A dopamine beta hydroxylase (DBH) gene promoter variant is associated with migraine susceptibility. This finding suggests a potential role for DBH genetic variations in the neurological disorder.
Area of Science:
- Neurogenetics
- Pharmacogenetics
Background:
- Migraine is a prevalent neurological disorder with a known genetic influence.
- Previous research suggests a link between dopamine system variations and migraine.
- Our lab previously identified an association between a dopamine beta hydroxylase (DBH) gene promoter marker and migraine.
Purpose of the Study:
- To investigate the association of two additional, potentially functional, dopamine beta hydroxylase (DBH) gene markers with migraine.
- To analyze a promoter single nucleotide polymorphism (SNP) (-1021C-->T) and an exon 11 SNP (+1603C-->T) in independent migraine cohorts.
Main Methods:
- Case-control study design utilizing two independent migraine cohorts.
- Genotyping of two DBH gene markers: a promoter SNP (-1021C-->T) and an exon 11 SNP (+1603C-->T).
- Statistical analysis of allelic and genotypic frequencies to determine association with migraine.
Main Results:
- A significant association was found between the DBH promoter marker (-1021C-->T) and migraine in both cohorts (P = 0.004-0.031).
- No significant association was observed between the DBH exon 11 marker (+1603C-->T) and migraine in either cohort (P >= 0.05).
- The associated promoter DBH marker influences plasma DBH activity, which is linked to dopamine levels and migraine severity.
Conclusions:
- The functional promoter variant of the dopamine beta hydroxylase (DBH) gene is significantly associated with migraine.
- This genetic variation may contribute to migraine susceptibility by affecting DBH enzyme activity and dopamine regulation.
- Further research into DBH gene variants could elucidate migraine pathophysiology.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:28Human Genetics
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:11Genetic Lingo
Overview
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...